SCAT Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==SCAT Trial== ===Objective=== To assess the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on co..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To assess the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary [[atherosclerosis]] in normocholesterolemic patients. | To assess the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary [[atherosclerosis]] in normocholesterolemic patients. | ||
==Methods== | |||
The [[Simvastatin]]/[[Enalapril]] Coronary Atherosclerosis Trial (SCAT) was a multicentered, randomized, double blinded, placebo-controlled angiographic trial wherein a total of 460 normocholesterolemic patients were enrolled. 230 received simvastatin, 230 a simvastatin placebo, 229 enalapril and 231 an enalapril placebo. All the patients were followed up for an average time period of 47.8 months. | The [[Simvastatin]]/[[Enalapril]] Coronary Atherosclerosis Trial (SCAT) was a multicentered, randomized, double blinded, placebo-controlled angiographic trial wherein a total of 460 normocholesterolemic patients were enrolled. 230 received simvastatin, 230 a simvastatin placebo, 229 enalapril and 231 an enalapril placebo. All the patients were followed up for an average time period of 47.8 months. | ||
==Results== | |||
Less progression was observed in patients receiving simvastatin compared to those receiving [[placebo]]. On quantitative coronary angiography the change in mean diameter, minimum diameter, percentage [[stenosis]] and the need for angioplasty was less with simvastatin. No additional benefit was observed with enalapril therapy.<ref name="pmid11023927">{{cite journal |author=Teo KK, Burton JR, Buller CE, ''et al.'' |title=Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) |journal=Circulation |volume=102 |issue=15 |pages=1748–54 |year=2000 |month=October |pmid=11023927 |doi= |url=}}</ref><ref name="pmid1271748">{{cite journal |author=Crawford DW, Barndt R, Back LH |title=Surface characteristics of normal and atherosclerotic human arteries including observations suggesting interaction between flow and intimal morphology |journal=Lab. Invest. |volume=34 |issue=5 |pages=463–70 |year=1976 |month=May |pmid=1271748 |doi= |url=}}</ref><ref name="pmid9215232">{{cite journal |author=Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ |title=Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators |journal=Can J Cardiol |volume=13 |issue=6 |pages=591–9 |year=1997 |month=June |pmid=9215232 |doi= |url=}}</ref> | Less progression was observed in patients receiving simvastatin compared to those receiving [[placebo]]. On quantitative coronary angiography the change in mean diameter, minimum diameter, percentage [[stenosis]] and the need for angioplasty was less with simvastatin. No additional benefit was observed with enalapril therapy.<ref name="pmid11023927">{{cite journal |author=Teo KK, Burton JR, Buller CE, ''et al.'' |title=Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) |journal=Circulation |volume=102 |issue=15 |pages=1748–54 |year=2000 |month=October |pmid=11023927 |doi= |url=}}</ref><ref name="pmid1271748">{{cite journal |author=Crawford DW, Barndt R, Back LH |title=Surface characteristics of normal and atherosclerotic human arteries including observations suggesting interaction between flow and intimal morphology |journal=Lab. Invest. |volume=34 |issue=5 |pages=463–70 |year=1976 |month=May |pmid=1271748 |doi= |url=}}</ref><ref name="pmid9215232">{{cite journal |author=Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ |title=Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators |journal=Can J Cardiol |volume=13 |issue=6 |pages=591–9 |year=1997 |month=June |pmid=9215232 |doi= |url=}}</ref> | ||
| Line 19: | Line 19: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Latest revision as of 23:21, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
SCAT Trial On the Web |
|
American Roentgen Ray Society Images of SCAT Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To assess the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis in normocholesterolemic patients.
Methods
The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) was a multicentered, randomized, double blinded, placebo-controlled angiographic trial wherein a total of 460 normocholesterolemic patients were enrolled. 230 received simvastatin, 230 a simvastatin placebo, 229 enalapril and 231 an enalapril placebo. All the patients were followed up for an average time period of 47.8 months.
Results
Less progression was observed in patients receiving simvastatin compared to those receiving placebo. On quantitative coronary angiography the change in mean diameter, minimum diameter, percentage stenosis and the need for angioplasty was less with simvastatin. No additional benefit was observed with enalapril therapy.[1][2][3]
References
- ↑ Teo KK, Burton JR, Buller CE; et al. (2000). "Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)". Circulation. 102 (15): 1748–54. PMID 11023927. Unknown parameter
|month=ignored (help) - ↑ Crawford DW, Barndt R, Back LH (1976). "Surface characteristics of normal and atherosclerotic human arteries including observations suggesting interaction between flow and intimal morphology". Lab. Invest. 34 (5): 463–70. PMID 1271748. Unknown parameter
|month=ignored (help) - ↑ Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ (1997). "Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators". Can J Cardiol. 13 (6): 591–9. PMID 9215232. Unknown parameter
|month=ignored (help)